Page 1 of 1

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)

PostPosted: Fri Jan 05, 2018 12:51 pm
by QualityStocks
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

Re: PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)

PostPosted: Fri Jan 05, 2018 6:13 pm
by QualityStocks
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is “One to Watch”

- Developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression
- Global market for cancer treatments projected to reach $161.3 billion by 2021
- Unique Sol-gel nose-to-brain CBD delivery platform under development to provide clinical relief of various physical disorders
- Global neuropathic pain market estimated at $8.3 billion by 2024
- Proof of concept already demonstrated for dual-gene therapy for type 2 diabetes and obesity
- Global expenditure for diabetes market in 2016 reached $825 billion

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

For more information, visit the company’s website at www.PreveCeutical.com

Re: PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)

PostPosted: Mon Jan 08, 2018 6:21 pm
by QualityStocks
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Utilizes Caribbean Blue Scorpion Venom in Proprietary CELLB9

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression. An article discussing this reads: “The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.”

Re: PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)

PostPosted: Fri Jan 12, 2018 9:26 pm
by QualityStocks
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Receives Initial Coverage from Crystal Equity Research

On January 9, 2018, Crystal Equity Research published an initial report on PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (http://nnw.fm/aO8gG), a biomedical company with a focus on preventative health sciences. Among other highlights, the report noted the company’s recapitalization efforts to fund its development program, as well as the strategic mergers and distribution agreements to address additional markets, including the sports medicine market. The company’s initial product, CELLB9, is an innovative therapy based on blue scorpion venom. The sales from CELLB9 represent the company’s current revenue stream, which helps to balance out research and developmental spending.

Re: PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)

PostPosted: Fri Jan 19, 2018 6:56 pm
by QualityStocks
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Combining Nature and Science to Make Life Better

- Company utilizing novel Caribbean blue scorpion venom therapy for immune system boost
- PreveCeutical seeks new ways to treat cancers, metabolic disorders, pain, infectious diseases and cardiovascular disease
- Partnership with University of Queensland researchers advances scientific scope of projects

In the modern health care industry, disease prevention has taken a commanding role as screenings and regularly scheduled physician visits aim to minimize costs that could otherwise spiral out of control once a chronic condition is established. However, the Centers for Disease Control and Prevention report an ongoing concern that Americans are using preventive services at about half the recommended rate (http://nnw.fm/b93YW). British Columbia-based PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the principle that prevention is the best policy in health care and that nature and science may combine to provide an array of innovative, untapped solutions to otherwise unmet clinical needs.

PreveCeutical is taking a new look at ways to combat chronic health concerns such as diabetes and obesity, pain management, neurological disorders and cancer. PreveCeutical developed its CELLB9® oral dilute solution utilizing select peptides from the blue scorpion, which is found only in the Caribbean region. PreveCeutical’s “Nature Identical” research team is building on proprietary chemistry to produce controlled venom peptides that it hopes will be able to halt the progression of cancers, while also exploring the peptides’ potential in responding to other medical concerns related to metabolic disorders, pain, cardiovascular disease and infectious maladies.

During 2017, the company entered a partnership with UniQuest Pty Limited that directs UniQuest to conduct research programs at the University of Queensland in Australia on PreveCeutical’s behalf. The partnership identified development programs for four therapies.

One of those is aimed at assessing pain and inflammation models with the idea of developing non-addictive analgesics for moderate to severe pain. The three-phase research project was expected to last up to 24 months under the terms of the research and option agreement (http://nnw.fm/MdVB9) with the goal of identifying the scorpion peptides and a means of replicating them in a laboratory, rather than having to rely on milking the scorpions for their venom, then screening the peptides in various disease models of interest.

PreveCeutical is also developing a proprietary gel application, called Sol-gels, for delivering a CBD-based medical cannabis formulation directly to the brain. Sol-gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines – eliminating first-pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.

The company’s four-year program targeting diabetes and obesity seeks also to engineer a therapy that recognizes a gene common and overactive in the two ailments. The therapy would “silence” the gene — turning it off to prevent the overproduction of a protein molecule believed to play a role in the declines commonly associated with diabetes and obesity.

Successes in these endeavors would solidify PreveCeutical’s efforts to become recognized as a pioneer in preventative medicine and increased quality of life factors.

For more information, visit the company’s website at www.PreveCeutical.com